We use cookies for a better user experience. Read our Privacy Policy
I Agree
Structural Heart Devices Market
Structural heart devices technology has seen a paradigm shift with the advent of non-invasive procedures to treat aortic stenosis and mitral regurgitation. From a previously sluggish approach, there seems to be a spate of activity characterized by investor excitement and massive research & development (R&D) initiatives regarding minimally-invasive heart valve technologies. For cardio-thoracic surgeons and interventional cardiologists, this arena offers tremendous scope and potential vis-à-vis traditional open heart surgery that is associated with severe side-effects.
Industry leaders and clinicians are viewing this as the answer to the growing unmet need of treating patients, with lesser hospitalization and a better prognosis. This is fueling the growth of innovations in the structural heart devices market. With the market poised to grow at a CAGR of 7.5% over the forecast period, the global structural heart devices market offers lucrative opportunities to emerging market players who are trying to gain a foothold in an industry that has lush benefits.
Tissue Engineered Heart Valves (TEHV), or biological valves, offer a new and advanced genre of treatment for patients who are in need of complete or partial valve replacement. Heart valves that are tissue engineered are a novel example of a live heart valve that consists of the host’s own tissues and cells. The biologic/tissue valves was the largest sector and accounted for ~55% of the market share in the year 2018. This is likely to reach a valuation of US$ 8 Bn by the end of the year 2027. The large-scale availability of transcatheter tissue valves and their adoption will fuel the growth of the structural heart devices market.
Xeltis is a clinical-stage medical device company that champions restorative solutions in patients needing cardiovascular therapy. Its structural heart devices sector has pioneered a procedure called Endogenous Tissue Restoration (ETR). Through this procedure, the patient is naturally able to restore a damaged heart valve. The latest innovation has been to use a polymer-based technology to restore cardiac function using ETR. With time, these devices can be developed on a large scale, obviating the cumbersome manufacturing processes involved with traditional biologic devices. Similarly, LivaNova’s ‘Perceval’ is the only suture-less, aortic tissue valve that is minimally-invasive, and is designed to be highly versatile in complex cardiomyopathy and acute cases of valvular stenosis. As these new devices are made available globally, the structural devices market will see new innovations and will gain momentum over the forecast period.
To know the segments analyzed in the TMR report, ask for a brochure here.
Since structural heart diseases pertain to abnormalities in the heart’s anatomy, and these can lead to serious complications such as stroke, cardiac arrest, and heart failure. Traditionally, the only way to treat structural heart diseases was through an open heart surgery. In Aug 2019, the Food and Drug Administration (FDA) approved transcatheter aortic valve replacement (TAVR) as a suitable replacement technology for patients suffering from severe aortic stenosis. This procedure is highly recommended for patients who are younger and lead more active lifestyles.
Experts opine that, the recent FDA approval was in the offing, due to the procedure’s stupendous success in clinical trials. Its approval in low-risk patients paves the way for its proliferation over the next two years, as it will replace surgical valve replacement in a big way. The replacement procedures sector has been gaining significant momentum, and captured ~77% of the market share in the year 2018. The popularity and user-friendliness of TAVR procedures is likely to fuel the growth of the structural devices market over the next decade.
To know more about TMRs unique offerings for Structural Heart Devices Market, request a sample here
Winning Imperatives: R&D and Innovation to Fuel Structural Heart Devices Market
North America held a prominent share of the market in the year 2018. The structural devices market in North America is fueled by innovative procedures, research & development, and new product launches. For this reason, North America accounted for 42% of the global market in the year 2018.
Interventional catheter technologies are the new technologies and innovations that are shaping the structural heart devices market, of not only North America, but also the global market space. Hybrid procedures, healthcare reforms, and collaborations amongst surgeons, interventionists, and cardiologists will drive the growth of the structural heart devices landscape.
Get a snapshot of the latest report on Structural Heart Devices Market with Custom Report here
New Product Launches and Acquisitions Define the Competitive Landscape
The competitive landscape of the structural heart devices market is highly consolidated with four major players, Edward Lifesciences Corporation, Abbott, Medtronic, and Boston Scientific Corporation account for ~92% of the total market share. Their growth strategy is centered around product innovations, patient care, and transformative catheter procedures.
Edward Lifesciences and Medtronic are the dominant leaders in the structural heart devices market landscape, and their rapid rise can be attributed to acquisitions, collaborations, product innovations, and sophisticated distribution channels that have allowed them to grow globally.
Edward Lifesciences has pioneered TAVR, which was approved by the FDA in Aug 2019. This innovative solution has further consolidated its position as a global leader in transformative healthcare, and has aided it in propelling ahead in the structural heart devices market. Its other product offerings are the SAPIEN 3 and SAPIEN XT. SAPIEN 3 is a trans-catheter heart valve that is artificial, and there are several accessories used to implant the valve without an open heart surgery. In Feb 2019, Edward Lifesciences entered into a merger agreement to acquire CAS Medical Systems, a medical technology company that deals with non-invasive monitoring of oxygen in the brain. This will strengthen Edward’s leadership in smart monitoring capabilities.
In Aug 2019, Medtronic announced the U.S FDA approval of its Evolut TAVR system for patients suffering from native stenosis. Evolut offers an excellent safety solution for low-risk patients with minimum hospital stay and excellent quality of life. In May 2019, Medtronic announced its decision to acquire Titan Spine, a privately-held titanium spine inter-body implant and surface technology company. With this merger, Medtronic will acquire Titan Spine’s entire range of innovative spinal titanium fusion devices. This will have a dramatic impact on both, the cardiac and spine market, and will fuel Medtronic’s growth in the structural heart devices market.
Micro Interventional Devices, Inc is an emerging player that designs and manufactures disruptive technologies for usage in structural heart repair procedures. Its products like the permavalve is a new-found catheter-based solution, and is said to drive the structural heart devices market.
In Mar 2019, Micro Interventional Devices Inc entered into a strategic alliance with OSCAR Inc. With this, both companies will be able to spearhead innovative solutions for structural heart diseases, and leverage their place in the market. Under this agreement, Micro Interventional Devices Inc acquires a global license to OSCAR’s patented catheter technology. This will give Micro Interventional Devices the technical prowess to ramp up production and enhance its revenue portfolio.
Analysts’ Perspective
A comprehensive view of the structural heart devices market has led our analysts to conclude that, the market is growing at a high CAGR, with North America holding a large chunk of the global demand for structural heart devices and their applications. The rising demand for structural heart device technology and its versatile applications in the treatment of cardiac diseases is spurring its demand. The impact of new innovations and product launches in the field of valve replacement will remain high on the structural heart devices market, globally. Strong financial position, acquisition strategies, and technological innovations of key market players will also give impetus to the structural heart devices market.
Technological breakthroughs such as TAVR and Hybrid therapy could provide timely relief as a cost-effective and time-saving strategy, thereby increasing profit margins for market players. Companies with research & development capabilities and technological prowess will gather momentum and profitability in the structural heart devices market. Leading players who are leveraging technology will continue to grow exponentially and have a vast market revenue share. However, stringent government regulations and high cost of minimally-invasive procedures could restrain the growth of the structural heart devices market.
Surge in Minimally-invasive Procedures: A Key Driver
Increase in Awareness about Structural Heart Devices and Favorable Reimbursement Policies Drive Market
Global Structural Heart Devices Market: Key Segments
Structural Heart Devices Market: Competitive Landscape
Structural Heart Devices Market: Key Developments
In the global structural heart devices market report, we have discussed individual strategies, followed by company profiles of the manufacturers of structural heart devices. The competitive landscape section is included in the report to provide readers with a dashboard view and a company market share analysis of the key players operating in the global structural heart devices market.
Structural Heart Devices Market – Segmentation
In order to understand the finer details of the market, the report segments the structural heart devices market on the basis of product, procedure, indication, and region. This allows market stakeholders to assess incremental opportunities in this market landscape.
|
Product |
Biological/Tissue Valves
Mechanical Heart Valves Annuloplasty Rings Occluders Accessories |
|
Procedure |
Replacement Procedures Repair Procedures |
|
Indication |
Valve Stenosis Valve Regurgitation Cardiomyopathy Congenital Heart Defects Others |
|
Region |
North America Europe Asia Pacific Middle East and Africa Latin America |
Structural heart devices market is estimated to reach ~US$ 13 Bn by 2027
Structural heart devices market to Expand at a CAGR of 7.5% from 2019 to 2027
Structural heart devices market is driven by surge in the awareness about structural heart diseases and favorable reimbursement policies
The biological/tissue valves segment accounted for a leading share of the global structural heart devices market and to dominate the global market during the forecast period
Key players in the global structural heart devices market are Medtronic, Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Structural Heart Devices Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Surge in awareness about structural heart diseases
4.3.1.2. Rise in prevalence of structural heart diseases
4.3.1.3. Increase in demand for minimally invasive procedures
4.3.1.4. Technological advancements in structural heart devices
4.3.1.5. Favorable reimbursement policies
4.3.1.6. Longer life expectancy along with increase in geriatric population
4.3.2. Restraints
4.3.2.1. Stringent government approval process
4.3.2.2. High cost of minimally invasive procedures
4.3.3. Opportunities
4.3.3.1. Lucrative opportunities in emerging markets
4.3.3.2. Increase in demand for heart valve repair procedures
4.4. Global Structural Heart Devices Market Analysis and Forecast, 2019–2027
5. Market Outlook
5.1. Product Mapping
5.2. Trials Mapping
5.3. Price Comparison Analysis
5.4. Technological Advancements
5.5. Key Industry Events
6. Global Structural Heart Devices Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2019–2027
6.3.1. Biological/Tissue Valves
6.3.1.1. Transcatheter Heart Valves
6.3.1.2. Surgical Heart Valve
6.3.2. Mechanical Heart Valves
6.3.3. Annuloplasty Rings
6.3.4. Occluders
6.3.5. Accessories
6.4. Market Attractiveness, by Product
7. Global Structural Heart Devices Market Analysis and Forecast, by Procedure
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Procedure, 2019–2027
7.3.1. Replacement Procedure
7.3.2. Repair Procedure
7.4. Market Attractiveness, by Procedure
8. Global Structural Heart Devices Market Analysis and Forecasts, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2019–2027
8.3.1. Valve Stenosis
8.3.2. Valve Regurgitation
8.3.3. Cardiomyopathy
8.3.4. Congenital Heart Defects
8.3.5. Others
8.4. Market Attractiveness, by Indication
9. Global Structural Heart Devices Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Structural Heart Devices Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2019–2027
10.2.1. Biological/Tissue Valves
10.2.1.1. Transcatheter Heart Valves
10.2.1.2. Surgical Heart Valve
10.2.2. Mechanical Heart Valves
10.2.3. Annuloplasty Rings
10.2.4. Occluders
10.2.5. Accessories
10.3. Market Value Forecast, by Procedure, 2019–2027
10.3.1. Replacement Procedure
10.3.2. Repair Procedure
10.4. Market Value Forecast, by Indication, 2019–2027
10.4.1. Valve Stenosis
10.4.2. Valve Regurgitation
10.4.3. Cardiomyopathy
10.4.4. Congenital Heart Defects
10.4.5. Others
10.5. Market Value Forecast, by Country, 2019–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Procedure
10.6.3. By Indication
10.6.4. By Country
11. Europe Structural Heart Devices Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2019–2027
11.2.1. Biological/Tissue Valves
11.2.1.1. Transcatheter Heart Valves
11.2.1.2. Surgical Heart Valve
11.2.2. Mechanical Heart Valves
11.2.3. Annuloplasty Rings
11.2.4. Occluders
11.2.5. Accessories
11.3. Market Value Forecast, by Procedure, 2019–2027
11.3.1. Replacement Procedure
11.3.2. Repair Procedure
11.4. Market Value Forecast, by Indication, 2019–2027
11.4.1. Valve Stenosis
11.4.2. Valve Regurgitation
11.4.3. Cardiomyopathy
11.4.4. Congenital Heart Defects
11.4.5. Others
11.5. Market Value Forecast, by Country/Sub-region, 2019–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Procedure
11.6.3. By Indication
11.6.4. By Country/Sub-region
12. Asia Pacific Structural Heart Devices Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2019–2027
12.2.1. Biological/ Tissue Valves
12.2.1.1. Transcatheter Heart Valves
12.2.1.2. Surgical Heart Valve
12.2.2. Mechanical Heart Valves
12.2.3. Annuloplasty Rings
12.2.4. Occluders
12.2.5. Accessories
12.3. Market Value Forecast, by Procedure, 2019–2027
12.3.1. Replacement Procedure
12.3.2. Repair Procedure
12.4. Market Value Forecast, by Indication, 2019–2027
12.4.1. Valve Stenosis
12.4.2. Valve Regurgitation
12.4.3. Cardiomyopathy
12.4.4. Congenital Heart Defects
12.4.5. Others
12.5. Market Value Forecast, by Country/Sub-region, 2019–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Procedure
12.6.3. By Indication
12.6.4. By Country/Sub-region
13. Latin America Structural Heart Devices Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2019–2027
13.2.1. Biological/ Tissue Valves
13.2.1.1. Transcatheter Heart Valves
13.2.1.2. Surgical Heart Valve
13.2.2. Mechanical Heart Valves
13.2.3. Annuloplasty Rings
13.2.4. Occluders
13.2.5. Accessories
13.3. Market Value Forecast, by Procedure, 2019–2027
13.3.1. Replacement Procedure
13.3.2. Repair Procedure
13.4. Market Value Forecast, by Indication, 2019–2027
13.4.1. Valve Stenosis
13.4.2. Valve Regurgitation
13.4.3. Cardiomyopathy
13.4.4. Congenital Heart Defects
13.4.5. Others
13.5. Market Value Forecast, by Country/Sub-region, 2019–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Procedure
13.6.3. By Indication
13.6.4. By Country/Sub-region
14. Middle East & Africa Structural Heart Devices Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2019–2027
14.2.1. Biological/ Tissue Valves
14.2.1.1. Transcatheter Heart Valves
14.2.1.2. Surgical Heart Valve
14.2.2. Mechanical Heart Valves
14.2.3. Annuloplasty Rings
14.2.4. Occluders
14.2.5. Accessories
14.3. Market Value Forecast, by Procedure, 2019–2027
14.3.1. Replacement Procedure
14.3.2. Repair Procedure
14.4. Market Value Forecast, by Indication, 2019–2027
14.4.1. Valve Stenosis
14.4.2. Valve Regurgitation
14.4.3. Cardiomyopathy
14.4.4. Congenital Heart Defects
14.4.5. Others
14.5. Market Value Forecast, by Country/Sub-region, 2019–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Procedure
14.6.3. By Indication
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company, 2018
15.3. Company Profiles
15.3.1. Medtronic
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. CryoLife, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Abbott
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Boston Scientific Corporation
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Edwards Lifesciences Corporation
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. LivaNova PLC
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Lepu Medical
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Micro Interventional Devices, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Lifetech Scientific
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
List of Tables
Table 01: Structural Heart Device Product Mapping (1/6)
Table 02: Structural Heart Device Product Mapping (2/6)
Table 03: Structural Heart Device Product Mapping (3/6)
Table 04: Structural Heart Device Product Mapping (4/6)
Table 05: Structural Heart Device Product Mapping (5/6)
Table 06: Structural Heart Device Product Mapping (6/6)
Table 07: Ongoing Structural Heart Device Pipeline Analysis (1/7)
Table 08: Ongoing Structural Heart Device Pipeline Analysis (2/7)
Table 09: Ongoing Structural Heart Device Pipeline Analysis (3/7)
Table 10: Ongoing Structural Heart Device Pipeline Analysis (4/7)
Table 11: Ongoing Structural Heart Device Pipeline Analysis (5/7)
Table 12: Ongoing Structural Heart Device Pipeline Analysis (6/7)
Table 13: Ongoing Structural Heart Device Pipeline Analysis (7/7)
Table 14: Average Heart Valve Pricing (US$), 2017–2018
Table 15: Average Heart Valve Pricing (US$), 2017–2018
Table 16: Average Heart Valve Pricing (US$), 2017
Table 17: Global Structural Heart Devices Market, Product Launch and Regulatory Approvals, 2018–2019
Table 18: Global Structural Heart Devices Market, Product Launch and Regulatory Approvals, 2017–2018
Table 19: Global Structural Heart Devices Market, Product Launch and Regulatory Approvals, 2016–2017
Table 20: Global Structural Heart Devices Market, Acquisitions, 2016–2019
Table 21: Global Structural Heart Devices Market, Partnerships, Collaborations and Alliances, 2017–2019
Table 22: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Product, 2017–2027
Table 23: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
Table 24: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Procedure, 2017–2027
Table 25: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Indication, 2017–2027
Table 26: Global Structural Heart Devices Market Size (US$ Mn) Forecast, by Region, 2017–2027
Table 27: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 28: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
Table 29: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
Table 30: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 31: North America Structural Heart Devices Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 32: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 33: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
Table 34: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
Table 35: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 36: Europe Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 37: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 38: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
Table 39: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
Table 40: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 41: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 42: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 43: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
Table 44: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
Table 45: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 46: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 47: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 48: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Biological/Tissue Valves, 2017–2027
Table 49: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Procedure, 2017–2027
Table 50: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 51: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
List of Figures
Figure 01: Global Structural Heart Devices Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Structural Heart Devices Market Value (US$ Mn), by Product, 2018
Figure 03: Global Structural Heart Devices Market Top Two Trends, by Procedure and Indication, 2018
Figure 04: Global Structural Heart Devices Market Overview
Figure 05: Global Structural Heart Devices Market Value Share, by Product, 2018
Figure 06: Global Structural Heart Devices Market Value Share, by Procedure, 2018
Figure 07: Global Structural Heart Devices Market Value Share, by Indication, 2018
Figure 08: Global Structural Heart Devices Market Value Share, by Region, 2018
Figure 09: Global Structural Heart Devices Market Value (US$ Mn) Forecast, 2017–2027
Figure 10: Key Market Developments
Figure 11: Global Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
Figure 12: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Biological/Tissue Valves, 2017–2027
Figure 13: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, Mechanical Heart Valves, 2017–2027
Figure 14: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Annuloplasty Rings, 2017–2027
Figure 15: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, Occluders, 2017–2027
Figure 16: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Accessories, 2017–2027
Figure 17: Global Structural Heart Devices Market Attractiveness Analysis, by Product, 2018–2026
Figure 18: Global Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
Figure 19: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Replacement Procedures, 2017–2027
Figure 20: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Repair Procedures, 2017–2027
Figure 21: Global Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2018–2027
Figure 22: Global Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
Figure 23: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Valve Stenosis, 2017–2027
Figure 24: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Valve Regurgitation, 2017–2027
Figure 25: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Cardiomyopathy, 2017–2027
Figure 26: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Congenital Heart Defects, 2017–2027
Figure 27: Global Structural Heart Devices Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
Figure 28: Global Structural Heart Devices Market Attractiveness Analysis, by Indication, 2018–2027
Figure 29: Global Structural Heart Devices Market Value Share Analysis, by Region, 2018 and 2027
Figure 30: Global Structural Heart Devices Market Attractiveness Analysis, by Region, 2018–2026
Figure 31: North America Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 32: North America Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
Figure 33: North America Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
Figure 34: North America Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
Figure 35: North America Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
Figure 36: North America Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
Figure 37: North America Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019–2027
Figure 38: North America Structural Heart Devices Market Value Share Analysis, by Country, 2018 and 2027
Figure 39: North America Structural Heart Devices Market Attractiveness Analysis, by Country, 2019–2027
Figure 40: Europe Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 41: Europe Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
Figure 42: Europe Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
Figure 43: Europe Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
Figure 44: Europe Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
Figure 45: Europe Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
Figure 46: Europe Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019–2027
Figure 47: Europe Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 48: Europe Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 49: Asia Pacific Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 50: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
Figure 51: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
Figure 52: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
Figure 53: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
Figure 54: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
Figure 55: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019 -2027
Figure 56: Asia Pacific Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 57: Asia Pacific Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 58: Latin America Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 59: Latin America Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
Figure 60: Latin America Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
Figure 61: Latin America Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
Figure 62: Latin America Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
Figure 63: Latin America Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
Figure 64: Latin America Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019 -2027
Figure 65: Latin America Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 66: Latin America Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 67: Middle East & Africa Structural Heart Devices Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 68: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Product, 2018 and 2027
Figure 69: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Product, 2019–2027
Figure 70: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Procedure, 2018 and 2027
Figure 71: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Procedure, 2019?2027
Figure 72: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Indication, 2018 and 2027
Figure 73: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Indication, 2019–2027
Figure 74: Middle East & Africa Structural Heart Devices Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 75: Middle East & Africa Structural Heart Devices Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 76: Global Structural Heart Devices Market Share, by Company, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes